Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02834013CT.gov Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Ieramilimab | Novartis Pharmaceuticals | P2 | B |
| Cyclophosphamide | TCR2 Therapeutics | P1/2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Niraparib | CanariaBio Inc. | P2 | CCC |
| Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal Antibody | M.D. Anderson Cancer Center | P2 | CCC |
| Pasifolate Exatecan | Elucida Oncology | P1/2 | CCC |
| Fludarabine | TCR2 Therapeutics | P1/2 | CCC |
| Spartalizumab | Novartis Pharmaceuticals | P2 | CCC |
+7 more in the Ovarian Adenocarcinoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IeramilimabNovartis PharmaceuticalsB
- CyclophosphamideTCR2 TherapeuticsCCC
- IpilimumabNational Cancer Institute (NCI)CCC
- NiraparibCanariaBio Inc.CCC
- Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal AntibodyM.D. Anderson Cancer CenterCCC
Citation
Floatz Terminal. Nivolumab in Ovarian Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-ovarian-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →